These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28901950)

  • 1. Detecting drug-target binding in cells using fluorescence-activated cell sorting coupled with mass spectrometry analysis.
    Wilson K; Webster SP; Iredale JP; Zheng X; Homer NZ; Pham NT; Auer M; Mole DJ
    Methods Appl Fluoresc; 2017 Dec; 6(1):015002. PubMed ID: 28901950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A magnetic bead-based ligand binding assay to facilitate human kynurenine 3-monooxygenase drug discovery.
    Wilson K; Mole DJ; Homer NZ; Iredale JP; Auer M; Webster SP
    J Biomol Screen; 2015 Feb; 20(2):292-8. PubMed ID: 25296660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial expression of human kynurenine 3-monooxygenase: solubility, activity, purification.
    Wilson K; Mole DJ; Binnie M; Homer NZ; Zheng X; Yard BA; Iredale JP; Auer M; Webster SP
    Protein Expr Purif; 2014 Mar; 95(100):96-103. PubMed ID: 24316190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Surface Plasmon Resonance Assay for the Characterization of Small-Molecule Binding Kinetics and Mechanism of Binding to Kynurenine 3-Monooxygenase.
    Poda SB; Kobayashi M; Nachane R; Menon V; Gandhi AS; Budac DP; Li G; Campbell BM; Tagmose L
    Assay Drug Dev Technol; 2015 Oct; 13(8):466-75. PubMed ID: 26292018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore-Based Virtual Screening of Novel Competitive Inhibitors of the Neurodegenerative Disease Target Kynurenine-3-Monooxygenase.
    Gotina L; Seo SH; Kim CW; Lim SM; Pae AN
    Molecules; 2021 May; 26(11):. PubMed ID: 34073016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of human kynurenine-3-monooxygenase protects against 3-hydroxykynurenine-mediated apoptosis through bidirectional nonlinear feedback.
    Wilson K; Auer M; Binnie M; Zheng X; Pham NT; Iredale JP; Webster SP; Mole DJ
    Cell Death Dis; 2016 Apr; 7(4):e2197. PubMed ID: 27077813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition.
    Mimasu S; Yamagishi H; Kubo S; Kiyohara M; Matsuda T; Yahata T; Thomson HA; Hupp CD; Liu J; Okuda T; Kakefuda K
    Commun Biol; 2021 Feb; 4(1):159. PubMed ID: 33542467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lead discovery for human kynurenine 3-monooxygenase by high-throughput RapidFire mass spectrometry.
    Lowe DM; Gee M; Haslam C; Leavens B; Christodoulou E; Hissey P; Hardwicke P; Argyrou A; Webster SP; Mole DJ; Wilson K; Binnie M; Yard BA; Dean T; Liddle J; Uings I; Hutchinson JP
    J Biomol Screen; 2014 Apr; 19(4):508-15. PubMed ID: 24381207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
    Phillips RS; Anderson AD; Gentry HG; Güner OF; Bowen JP
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1705-1708. PubMed ID: 28302400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of kynurenine 3-monooxygenase inhibition.
    Amaral M; Levy C; Heyes DJ; Lafite P; Outeiro TF; Giorgini F; Leys D; Scrutton NS
    Nature; 2013 Apr; 496(7445):382-5. PubMed ID: 23575632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.
    Zhang S; Collier MEW; Heyes DJ; Giorgini F; Scrutton NS
    Arch Biochem Biophys; 2021 Jan; 697():108702. PubMed ID: 33275878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
    Winkler D; Beconi M; Toledo-Sherman LM; Prime M; Ebneth A; Dominguez C; Muñoz-Sanjuan I
    J Biomol Screen; 2013 Sep; 18(8):879-89. PubMed ID: 23690293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds.
    Jacobs KR; Guillemin GJ; Lovejoy DB
    SLAS Discov; 2018 Jul; 23(6):554-560. PubMed ID: 29420107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(6-phenylpyridazin-3-yl)benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors.
    Kimura H; Suda H; Kassai M; Endo M; Deai Y; Yahata M; Miyajima M; Isobe Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127753. PubMed ID: 33359168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis.
    Liddle J; Beaufils B; Binnie M; Bouillot A; Denis AA; Hann MM; Haslam CP; Holmes DS; Hutchinson JP; Kranz M; McBride A; Mirguet O; Mole DJ; Mowat CG; Pal S; Rowland P; Trottet L; Uings IJ; Walker AL; Webster SP
    Bioorg Med Chem Lett; 2017 May; 27(9):2023-2028. PubMed ID: 28336141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
    Toledo-Sherman LM; Prime ME; Mrzljak L; Beconi MG; Beresford A; Brookfield FA; Brown CJ; Cardaun I; Courtney SM; Dijkman U; Hamelin-Flegg E; Johnson PD; Kempf V; Lyons K; Matthews K; Mitchell WL; O'Connell C; Pena P; Powell K; Rassoulpour A; Reed L; Reindl W; Selvaratnam S; Friley WW; Weddell DA; Went NE; Wheelan P; Winkler C; Winkler D; Wityak J; Yarnold CJ; Yates D; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2015 Feb; 58(3):1159-83. PubMed ID: 25590515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-(6-(5-fluoro-2-(piperidin-1-yl)phenyl)pyridazin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)methanesulfonamide as a brain-permeable and metabolically stable kynurenine monooxygenase inhibitor.
    Tsuboi K; Kimura H; Nakatsuji Y; Kassai M; Deai Y; Isobe Y
    Bioorg Med Chem Lett; 2021 Jul; 44():128115. PubMed ID: 34015507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics.
    Maddison DC; Alfonso-Núñez M; Swaih AM; Breda C; Campesan S; Allcock N; Straatman-Iwanowska A; Kyriacou CP; Giorgini F
    PLoS Genet; 2020 Nov; 16(11):e1009129. PubMed ID: 33170836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase.
    Kim HT; Na BK; Chung J; Kim S; Kwon SK; Cha H; Son J; Cho JM; Hwang KY
    Cell Chem Biol; 2018 Apr; 25(4):426-438.e4. PubMed ID: 29429898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.